Zimmer Biomet has informed Bactiguard that they terminate the license agreement signed in 2022 covering multiple orthopedic product segments. The reason stated is the more complex and lengthier path with FDA than initially expected by Zimmer Biomet. The partnership with Zimmer Biomet within the trauma product segment, related to an agreement signed in 2019, remains in effect.
The extended exclusive license agreement had covered implants for hip and knee joint reconstruction, sports medicine, craniomaxillofacial and thoracic applications.
In 2019, Bactiguard and Zimmer Biomet partnered to develop orthopedic trauma implants with Bactiguard’s technology to prevent post-op infections. European regulatory clearance was obtained in 2021, based on Bactiguard’s Orthosyn trauma implant. Zimmer Natural Nail (ZNN) Bactiguard implants were launched in Europe and other select markets in 2Q21.
There will be no negative financial impact for Bactiguard for 2024 related to this termination. Bactiguard is in dialogue with the team at Zimmer Biomet to evaluate further details and the impact of the termination, and will revert with more information once available.
Zimmer Biomet has informed Bactiguard that they terminate the license agreement signed in 2022 covering multiple orthopedic product segments. The reason stated is the more complex and lengthier path with FDA than initially expected by Zimmer Biomet. The partnership with Zimmer Biomet within the trauma product segment, related to an agreement...
Zimmer Biomet has informed Bactiguard that they terminate the license agreement signed in 2022 covering multiple orthopedic product segments. The reason stated is the more complex and lengthier path with FDA than initially expected by Zimmer Biomet. The partnership with Zimmer Biomet within the trauma product segment, related to an agreement signed in 2019, remains in effect.
The extended exclusive license agreement had covered implants for hip and knee joint reconstruction, sports medicine, craniomaxillofacial and thoracic applications.
In 2019, Bactiguard and Zimmer Biomet partnered to develop orthopedic trauma implants with Bactiguard’s technology to prevent post-op infections. European regulatory clearance was obtained in 2021, based on Bactiguard’s Orthosyn trauma implant. Zimmer Natural Nail (ZNN) Bactiguard implants were launched in Europe and other select markets in 2Q21.
There will be no negative financial impact for Bactiguard for 2024 related to this termination. Bactiguard is in dialogue with the team at Zimmer Biomet to evaluate further details and the impact of the termination, and will revert with more information once available.
Copy to clipboard 
